Increased plasma TGF-<i>β</i>1 in patients with amyotrophic lateral sclerosis

Houi, Kouji; Kobayashi, Takaaki; Kato, Shigeaki; Mochio, Soichiro; Inoue, Kiyoharu

doi:10.1034/j.1600-0404.2002.01301.x

Cited by 65 publications

(35 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in contrast to levels in the CSF, decreases in immune factors (IL-5 and IL-2) and glutathione levels were also shown indicating decreased immune response with increased oxidative stress. In addition to inflammatory factors, levels of the anti-inflammatory factor transforming growth factor (TGF)-β1 were shown to increase in plasma from patients with ALS as compared with controls and was positively correlated with disease duration [135]. Similar observations were also observed in serum where TGF-β1 concentrations were higher in patients with ALS than in controls [136].…”

Section: Biomarkers Of Inflammationsupporting

confidence: 67%

Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis

Bowser

2017

Neurotherapeutics

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a highly heterogeneous disease with no effective treatment. Drug development has been hampered by the lack of biomarkers that aid in early diagnosis, demonstrate target engagement, monitor disease progression, and can serve as surrogate endpoints to assess the efficacy of treatments. Fluid-based biomarkers may potentially address these issues. An ideal biomarker should exhibit high specificity and sensitivity for distinguishing ALS from control (appropriate disease mimics and other neurologic diseases) populations and monitor disease progression within individual patients. Significant progress has been made using cerebrospinal fluid, serum, and plasma in the search for ALS biomarkers, with urine and saliva biomarkers still in earlier stages of development. A few of these biomarker candidates have demonstrated use in patient stratification, predicting disease course (fast vs slow progression) and severity, or have been used in preclinical and clinical applications. However, while ALS biomarker discovery has seen tremendous advancements in the last decade, validating biomarkers and moving them towards the clinic remains more elusive. In this review, we highlight biomarkers that are moving towards clinical utility and the challenges that remain in order to implement biomarkers at all stages of the ALS drug development process.

show abstract

Section: Biomarkers Of Inflammationsupporting

confidence: 67%

Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis

Bowser

2017

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…122 Other reported biochemical changes include increased serum levels of lipid peroxides in sporadic ALS, 123 and increased serum levels of matrix metalloproteinase-9 124 and transforming growth factor-1. 125 These biochemical changes are not specific to ALS and have low sensitivity.…”

Section: Biomarkersmentioning

confidence: 99%

Measures and markers in Amyotrophic Lateral Sclerosis

2004

View full text Add to dashboard Cite

“…In amyotrophic lateral sclerosis (ALS) the plasma concentration of TGF-β1 increases significantly with the duration of illness, suggesting that TGF-β1 is involved in the disease process of ALS (Houi et al, 2002).…”

Section: Notementioning

confidence: 99%